K-Clip® Debuts at China Structural Week, Pioneering a New Era in Transcatheter Tricuspid Valve Repair

Oct 18, 2024 08:00 CST Updated 08:00

H&H Healthcare

R&D and Producer of Interventional Medical Devices for Heart Disease

October 13, 2024, in the morningThe 8th China Structural Heart Disease Academic WeekThe opening ceremony was held inShanghaiHeld. Academic discussions and technical exchanges on the latest hot topics and difficult issues in structural heart disease were carried out. Focusing on key topics such as TAVR, mitral valve, tricuspid valve, pulmonary valve, left atrial appendage, congenital heart disease, and cardiomyopathy, the most cutting-edge academic content was shared.

HuiHe HealthcareCarrying itsWorld's FirstofK-Clip^®Transcatheter Tricuspid Annuloplasty SystemDebut at Structural Week, forTricuspid Valve Diseasehas injected a new vitality into the field of treatment. The innovation of this system lies in itsMinimally Invasive, without the need for cardiac arrest and extracorporeal circulation support, throughBlood VesselThe approach can complete the tricuspid annuloplasty.K-Clip^®SystemCompared with traditional open-chest surgery, it is significantlyReduced surgical trauma，Reduce Surgical RiskAndShorten postoperative recovery timeBetween，Protecting Patients' Cardiovascular and Cerebrovascular Systems, offering a brand-new treatment option for patients with severe tricuspid regurgitation.

Opening Ceremony

Opening Ceremony "Academic Session: Four-Way Eight-Reach" segment, Chairman of China Structural Week Conference, Academician of the Chinese Academy of Sciences, Zhongshan Hospital Affiliated to Fudan UniversityAcademician Ge JunboAbout "Clinical Considerations for Transcatheter Treatment of Tricuspid Regurgitation》Themed speech brought the academic atmosphere of the opening ceremony to a new height. Tricuspid regurgitation(TR) PatientsEtiologyIt has a significant impact on prognosis and management, with diuretics being the cornerstone of pharmacological therapy. Patients in the early stages of TR tend to tolerate it well with subtle symptoms; however, by the time surgical intervention is required, the patient's overall condition is often poor and frequently accompanied by complications.Multiple Organ Dysfunction`, leading to`High surgical risk(Perioperative mortality rate 8-10%). Patients need to be fully evaluated for transcatheter tricuspid valve treatment. T-TEER and TTVA can be used as early treatment options for patients with central regurgitation.TTVR is suitable for patients with relatively severe lesions that cannot be repaired.，Ectopic tricuspid valve is suitable for patients with more advanced lesions.CurrentlyTricuspid Valve InterventionTherapyStudies have proven able toImprove patients' quality of life and improve symptomsStatus, and propose that the short-term research goal for tricuspid regurgitation treatment shouldFocusing on improving the quality of life。

Comprehensive Press Conference

At the comprehensive press conference, Fuwai Hospital of the Chinese Academy of Medical SciencesProfessor Wu YongjianReleased "Chinese Expert Consensus on Transcatheter Treatment of Tricuspid Regurgitation》，Enhance the objective understanding of TR and TTVI systems among professionals in China，Clarify the Development Direction of TTVI in China, to prepare for the healthy and standardized development of this technology. At the same time, a detailed interpretation of the key points in the consensus is provided, highlighting the three major highlights of the consensus: staying at the forefront——IntroductionNew Classification of Tricuspid Valve Anatomy and Regurgitation, Latest Interventional Treatment Devices and Clinical Research Results, Definition of Study Endpoints, Tricuspid Valve Syndrome and Risk Prediction Models, etc. Clear and Practical - Based on research results from China and abroad as well as Chinese experience, some proposals are put forward.Clear and PracticalClinical RecommendationsSuch as the specific indications criteria for interventional treatment, selection criteria for different devices, and TR treatment plans for different etiologies. Highlight the essence —— identify the 10 most clinically relevant concerns.Core Issues and In-Depth Analysis, forming 10Core ViewpointsIt is beneficial for readers to quickly grasp the essence of the consensus.

Tricuspid Valve Forum

During the Tricuspid Valve Forum, Beijing Anzhen Hospital, Capital Medical UniversityProfessor Song Guangyuan,Operational Techniques and Strategy Improvements for Percutaneous Tricuspid Annuloplasty DevicesDeliver a keynote speech. OverviewTricuspid regurgitation is mainly caused by functional regurgitation, primary regurgitation, and pacemaker-related regurgitation. The current main treatment methods include edge-to-edge repair (T-TEER), annuloplasty, orthotopic replacement, and heterotopic replacement. It is particularly noted that the tricuspid valve leaflets are thinner compared to the mitral valve leaflets.Annuloplasty TechniqueCompared with other treatment methods, it has obvious advantages.K-Clip^®SystemIn TreatmentFunctional Tricuspid Regurgitation, SpecialEspecially the regurgitation caused by annulus dilation has been widely recognized by scholars both in China and internationally.K-Clip^®SystemTheSimple operation, sufficient annuloplasty strength, and good durability.Sex, these characteristics make it an important method for treating tricuspid regurgitation currently. In the future, the K-Clip via femoral venous access^®Paired with a dual-control curved catheter sheath, it is expected to achieve better ligation results.

At the conference site,K-Clip^®SystemHas attracted high attention from numerous experts and scholars. They all expressed that this system brings new hope for the treatment of tricuspid valve disease, itsMinimally Invasive, Efficient, SafeThe features will bring good news to more patients. In the future, with the further promotion and application of this system, it is believed that more patients will benefit from this innovative technology.